	US 11,883,508 B2
	Method for culturing 3-dimensional lung cancer organoid and method for preparing patient-derived xenograft animal model using same
Se Jin Jang, Seongnam-si (KR); Min Suh Kim, Seoul (KR); Young Ah Suh, Seoul (KR); Hye Min Mun, Seoul (KR); and Ju Hee Oh, Anseong-si (KR)
Assigned to ONCOCLEW CO., LTD., Seoul (KR)
Appl. No. 16/638,801
Filed by ONCOCLEW CO., LTD., Seoul (KR)
PCT Filed Aug. 13, 2018, PCT No. PCT/KR2018/009254 § 371(c)(1), (2) Date Feb. 13, 2020, PCT Pub. No. WO2019/035618, PCT Pub. Date Feb. 21, 2019.
Claims priority of application No. 10-2017-0103121 (KR), filed on Aug. 14, 2017.
Prior Publication US 2021/0128752 A1, May 6, 2021
Int. Cl. A61K 49/00 (2006.01); A01K 67/027 (2006.01); C12N 5/09 (2010.01)

CPC A61K 49/0008 (2013.01) [A01K 67/0271 (2013.01); C12N 5/0693 (2013.01); A01K 2207/12 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); C12N 2500/38 (2013.01); C12N 2501/11 (2013.01); C12N 2501/113 (2013.01); C12N 2501/115 (2013.01); C12N 2501/727 (2013.01); C12N 2513/00 (2013.01); C12N 2533/50 (2013.01)]

6 Claims

1. A method for preparing a patient-derived lung cancer organoid xenograft animal model, comprising the steps of:

(a) culturing lung cancer cells, which have been obtained by cellizing lung cancer tissue isolated from a lung cancer patient, with a cell culture substrate, to obtain a lung cancer organoid;

(b) subjecting the obtained organoid to treatment with an enzyme and then allowing reaction to proceed;

(c) adding, to the lung cancer organoid after step (b), a cell culture substrate, and performing culture so that a 3-dimensional lung cancer organoid is formed;

(d) removing the cell culture substrate from the 3-dimensional lung cancer organoid;

(e) encapsulating the 3-dimensional lung cancer organoid, from which the cell culture substrate has been removed, in a membrane and then solidifying the same; and

(f) transplanting, into a subject animal, the 3-dimensional lung cancer organoid obtained in step (e), wherein the transplanting into a subject animal does not comprise injection of the 3-dimensional lung cancer organoid by syringe.